ClinicalTrials.gg
CompletedNCT05153239Updated Oct 21, 2026

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

A Phase 3 interventional study of Irinotecan and Lurbinectedin in Relapsed Small Cell Lung Cancer, sponsored by PharmaMar. Completed at 210 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by PharmaMar · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
705
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing irinotecan in Small Cell Lung Carcinoma — 8 open to participants now, 8 under way, 2 of them phase 3. Irinotecan · Small Cell Lung Carcinoma.

Enrollment
Largest of 40
705 · median 61
Started
2022
with 1 other
Phase 3
6 of 40
2 open now
Registered
31st of 40
by date

Among the 40 studies testing irinotecan in Small Cell Lung Carcinoma, this one has the largest enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 31st registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

8 of the 40 studies testing irinotecan in Small Cell Lung Carcinoma are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing irinotecan in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

Read the detailed description

Approximately 705 Adult SCLC patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 who have failed one prior platinum-containing line with CTFI ≥ 30 days and controlled asymptomatic and pretreated Central Nervous System metastases will be enrolled and assigned to each treatment arm.

Central randomization will be implemented; patients will be assigned to each treatment arm at a 1:1:1 ratio.

An Independent Data Monitoring Committee (IDMC) will oversee the conduct of the study. The IDMC should have access to unblinded efficacy and safety data throughout the trial to enable timely and informed judgments about risks and benefits.

03

Conditions studied

  • Relapsed Small Cell Lung Cancer

Keywords

  • Relapsed Small Cell Lung Cancer
  • PharmaMar
  • Lurbinectedin
  • Irinotecan
  • Topotecan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written of the patient obtained before any study-specific procedure
  2. Age≥18 years
  3. or cytologically confirmed diagnosis of SCLC.
  4. One prior line of platinum-containing chemotherapy with/without or anti-PD-L1 (Note: at least 70% of patients included in the study have to be pretreated with anti-PD-1 or anti-PD-L1)
  5. Chemotherapy-free interval (CTFI, time from the last dose of platinum-containing chemotherapy to the occurrence of progressive disease) ≥ 30 days (independent of the immunotherapy maintenance, if applicable)
  6. Patients with history of Central Nervous System (CNS) can participate provided they are pretreated and radiologically stable (i.e., without evidence of progression) for at least 4 weeks by repeated imaging (note: repeated imaging should be performed during study screening), asymptomatic, and without requirement of treatment for at least 7 days before the first dose of study treatment
  7. (ECOG) PS ≤ 2
  8. Adequate hematological, renal, metabolic and hepatic function:

    1. ≥ 9.0 g/dL [patients may have received prior red blood cell (RBC) transfusion, if clinically indicated]; (ANC) ≥ 2.0 x 10\^9/L, and count ≥ 100 x 10\^9/L.
    2. (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x (ULN).
    3. Total ≤ 1.5 x ULN or direct bilirubin ≤ ULN.
    4. Albumin ≥ 3.0 g/dL.
    5. Calculated (CrCL) ≥ 30 mL/min (using Cockcroft and Gault's formula).
  9. At least three weeks since last prior antineoplastic treatment and recovery to grade ≤ 1 from any adverse event (AE) related to previous anticancer treatment (excluding sensory neuropathy, immune-related hypothyroidism, anemia, asthenia and alopecia, all grade ≤ 2) according to the National Cancer InstituteCommon Terminology Criteria for Adverse Events (NCICTCAE) v.5.
  10. Prior radiotherapy (RT): At least two weeks since completion of prophylactic cranial irradiation (PCI), and to any other site not previously specified.
  11. Evidence of non-childbearing status for women of (WOCBP). WOCBP must agree to use a highly effective measure up to seven months after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last medicinal product (IMP) dose.

Exclusion criteria

Exclusion Criteria:

  1. Platinum-naïve patients or patients pretreated with more than one prior chemotherapy regimen (including patients re-challenged with same initial regimen).
  2. Prior treatment with lurbinectedin, trabectedin, PM14, or topoisomerase I inhibitors (irinotecan, topotecan, etc.).
  3. Active or untreated and/or carcinomatous meningitis.
  4. Patients with limited-stage disease who are candidates for local or regional therapy, including PCI, thoracic RT or both, must have been offered that option and completed treatment or refused it prior to randomization.
  5. Concomitant diseases/conditions:

    1. History or presence of unstable angina, myocardial infarction, congestive heart failure, or valvular heart disease within last year.
    2. Symptomatic arrhythmia or any uncontrolled arrhythmia requiring ongoing treatment.
    3. Ongoing chronic alcohol consumption or cirrhosis with score B or C.
    4. Known Gilbert's disease.
    5. Active uncontrolled infection. Serious non-healing wound, ulcer or bone fracture. Presence of external drainages.
    6. Ongoing, treatment-requiring, non-neoplastic chronic liver disease of any origin. For , this includes positive tests for both Hepatitis B surface antigen (HBsAg) and quantitative Hepatitis B polymerase chain reaction (PCR). For , this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR. Subjects taking hepatitis related antiviral therapy within six months prior to the first dose of study drugs will also be excluded.
    7. Intermittent or continuous oxygen requirement within two weeks prior to randomization. Patients with confirmed or suspected diagnosis of diffuse interstitial lung disease or pulmonary fibrosis.
    8. Patients with a second invasive treated with chemotherapy and/or RT. Patients with a previous malignancy that was completely resected with curative intention three or more years prior to randomization, except treated in situ carcinoma of the cervix, basal or squamous cell skin carcinoma, and in situ transitional cell bladder carcinoma and who has been continuously in remission since then will be permitted.
    9. Limitation of the patient's ability to comply with the treatment or to follow the protocol.
    10. Documented or suspected invasive fungal infections requiring systemic treatment within 12 weeks of randomization.
    11. Known (HIV) infection.
    12. Any past or present chronic inflammatory colon and/or liver disease, past intestinal obstruction, pseudo or subocclusion or paralysis.
    13. Evident symptomatic pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.
    14. Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study (e.g.; COVID-19 disease).
  6. RT in more than 35% of the bone marrow.
  7. History of previous bone marrow and/or stem cell transplantation and allogenic transplant.
  8. Patient has received a live or within 30 days before the first dose of study intervention. Administration of inactivated vaccines is allowed.
  9. Impending need for RT (e.g., painful bone and/or risk of spinal cord compression).
  10. History of allergy or to any of the study drugs or any of their .
  11. Women who are pregnant or breast feeding and fertile patients (men and women) who are not able to use a highly effective method of
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
705 participants (actual)

Study arms

  • Experimental
    Lurbinectedin

    Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)

    Drug: Lurbinectedin

  • Experimental
    Lurbinectedin plus Irinotecan

    Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle): * Irinotecan (Day 1 and Day 8) * Lurbinectedin (Day 1)

    Drug: Irinotecan · Drug: Lurbinectedin

  • Active comparator
    Control arm

    Best Investigator's choice prior to randomization between: * Irinotecan on Day 1 q3wk * Topotecan on Days 1-5 q3wk

    Drug: Irinotecan · Drug: Topotecan

Interventions

  • Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk

  • Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk

    Also known as: PM01183

  • For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk

  • Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk

  • Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk

    Also known as: PM01183

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival (OS) will be calculated from the date of randomization to the date of death or last contact (in this case, survival will be censored on that date).

    Time frame: From the date of randomization to the date of death or last contact, up to 39 months

Secondary outcomes

  1. Progression-free survival by IRC (Independent Review Committee)

    Progression-free survival (PFS) will be calculated from the date of randomization to the date of documented progression per RECIST v.1.1 (Progressive disease is declared when there is an increase in sum of target disease ≥ 20%) or death (regardless of the cause of death). If the patient receives further antitumor therapy, withdraws from the study, or is lost to follow-up before progressive disease (PD), PFS will be censored at the date of last evaluable tumor assessment before the date of subsequent antitumor therapy.

    Time frame: From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months

  2. Progression-free survival by IA (Investigator Assessment)

    Progression-free survival (PFS) will be calculated from the date of randomization to the date of documented progression per RECIST v.1.1 (Progressive disease is declared when there is an increase in sum of target disease ≥ 20%) or death (regardless of the cause of death). If the patient receives further antitumor therapy, withdraws from the study, or is lost to follow-up before progressive disease (PD), PFS will be censored at the date of last evaluable tumor assessment before the date of subsequent antitumor therapy.

    Time frame: From the date of randomization to the date of progressive disease, death or last tumor assessment or further anticancer treatment, up to 39 months

  3. Overall response rate by IRC

    Overall response rate (ORR) will be the percentage of patients with complete or partial response as the best response obtained in any evaluation according to RECIST v.1.1. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is \> -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each.

    Time frame: From the date of randomization to the date of death or last contact, up to 39 months

  4. Overall response rate by IA

    Overall response rate (ORR) will be the percentage of patients with complete or partial response as the best response obtained in any evaluation according to RECIST v.1.1. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is \> -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each.

    Time frame: From the date of randomization to the date of death or last contact, up to 39 months

  5. Overall survival rate at 12 months

    Overall survival rate at 12 months is defined as the percentage of people who are still alive at 12 months after randomization.

    Time frame: At 12 months

  6. Overall survival rate at 24 months

    Overall survival rate at 24 months is defined as the percentage of people who are still alive at 24 months after randomization.

    Time frame: At 24 months

  7. Progression-free survival rate at 6 months by IRC

    Progression-free survival rate at 6 months is defined as the percentage of people who remain free from progression at 6 months after randomization

    Time frame: At 6 months

  8. Progression-free survival rate at 6 months by IA

    Progression-free survival rate at 6 months is defined as the percentage of people who remain free from progression at 6 months after randomization

    Time frame: At 6 months

  9. Progression-free survival rate at 12 months by IRC

    Progression-free survival rate at 12 months is defined as the percentage of people who remain free from progression at 12 months after randomization

    Time frame: At 12 months

  10. Progression-free survival rate at 12 months by IA

    Progression-free survival rate at 12 months is defined as the percentage of people who remain free from progression at 12 months after randomization

    Time frame: At 12 months

  11. Duration of response by IRC

    Duration of response (DoR) will be calculated from the date of first documentation of response per RECIST v.1.1 (complete or partial response, whichever occurs first) to the date of documented PD or death. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is \> -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each.

    Time frame: From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months

  12. Duration of response by IA

    Duration of response (DoR) will be calculated from the date of first documentation of response per RECIST v.1.1 (complete or partial response, whichever occurs first) to the date of documented PD or death. Progressive disease is declared when there is an increase in sum of target disease ≥ 20%, stable disease when the change is \> -30% and ≤ 20%, partial response when there is a decrease in sum of target disease ≥ 30%, and complete response when all lesions have disappeared or all lesions have disappeared and all nodal disease is \< 10 mm each.

    Time frame: From the date of first documentation of complete or partial response to the date of documented progression disease, death or last contact, up to 39 months

  13. Patient-reported outcomes

    To measure the quality of life of patients, the Lung Cancer Symptom Scale (LCSS) questionnaire will be analyzed.

    Time frame: At baseline and every six weeks (± one week) until end of treatment, up to 39 months

07

Study locations

210 sites
  • Ironwood Cancer & Research Centers
    Chandler, Arizona 85224, United States
  • Genesis Cancer and Blood
    Hot Springs, Arkansas 71913, United States
  • Florida Cancer Specialists - South
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists - North
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists - Panhandle
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialists - East
    West Palm Beach, Florida 33401, United States
  • Duly Health and Care
    Joliet, Illinois 60435, United States
  • Norton Cancer Institue, Downtown
    Louisville, Kentucky 40202, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Oncology Hematology West, PC (Grand Island)
    Grand Island, Nebraska 68803, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • FirstHealth Outpatient Cancer Center
    Pinehurst, North Carolina 28374, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • MultiCare Regional Cancer Center - Tacoma
    Tacoma, Washington 98405, United States
  • Froedtert Hospital/Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • The Chris Obrien Lifehouse
    Camperdown, New South Wales 2050, Australia
  • BRICC - Ballarat Health Services
    Ballarat Central, Victoria 3350, Australia
  • Box Hill Hospital Eastern Health Clinical School
    Box Hill, Victoria 3128, Australia
  • Northern Beaches Hospital
    Frenchs Forest, NSW 2086, Australia
  • Gosford Hospital GH - Central Coast Cancer Centre
    Gosford, 2250, Australia
  • Austin Hospital- Medical Oncology Unit
    Heidelberg, VIC 3084, Australia
  • St John of God Murdoch Hospital
    Murdoch, WA 6150, Australia
  • Cancer Care Wollongong
    Wollongong, NSW 2500, Australia
  • University Hospital Salzburg
    Salzburg, A-5020, Austria
  • Medizinische Universitaet Wien
    Vienna, A-1090, Austria
  • Antwerp University Hospital
    Edegem, Antwerp 2650, Belgium
  • Algemeen Ziekenhuis AZ Klina - Borstkliniek
    Brasschaat, 2930, Belgium
  • Grand Hopital de Charleroi GHdC - Hopital Saint Joseph
    Charleroi, 6000, Belgium
  • Centre Hospitalier Chretien CHC - MontLegia
    Liège, 4000, Belgium
  • CHR de la Citadelle
    Liège, 4000, Belgium
  • CHU Liege
    Liège, 4000, Belgium
  • Az Sint Maarten Mechelen
    Mechelen, 2800, Belgium
  • Centre Hospitalier Universitaire (CHU) Ambroise Pare
    Mons, 7000, Belgium
  • Oncocentro-Centro de Oncologia do Parana
    Curitiba, Paraná 82305-100, Brazil
  • Irmandade daSanta Casa de Misericordia de Porto Alegre
    Porto Alegre, Porto Alegre 90050-170, Brazil
  • Hospital Sao Lucas da PUCRS
    Porto Alegre, Porto Alegre 90610-000, Brazil
  • UPCO - Hospital de Clinicas de Porto Alegre
    Santa Cecília, Porto Alegre RS 90035-903, Brazil
  • Nucleo de Oncologia da Bahia - NOB
    Ondina, Salvador BA 40170-110, Brazil
  • Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor
    Barretos, SP 14784-400, Brazil
  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia Ltda
    Ijuí, 98700-00, Brazil
  • Instituto Nacional de Cancer - Ministrio da Sade
    Rio de Janeiro, 20231-050, Brazil
  • Multiprofile Hospital for Active Treatment - Uni Hospital OOD Department of Medical Oncology
    Panagyurishte, Panagyurishte 4500, Bulgaria
  • Complex Oncology Center - Plovdiv EOOD, First Department of Medical Oncology and Oncological Diseases in Gastroenterology
    Plovdiv, 4000, Bulgaria
  • Specialized hospital for active treatment of oncological diseases
    Sofia, 1303, Bulgaria
  • Multiprofile Hospital for Active Treatment Serdika EOOD Second Department of Medical Oncology
    Sofia, 1632, Bulgaria
  • Hamilton Health Sciences -Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • Southlake Regional Health Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • Hôpital de la Cité-de-la- Santé
    Laval, Quebec H7M 3L9, Canada
  • CISSS de la Montérégie-Centre - Hôpital Charles LeMoyne
    Longueuil, Quebec J4V 2H1, Canada
  • McGill University Health Centre (MUHC)
    Montreal, H4A 3J1, Canada
  • University Health Network - Princess Margaret Hospital
    Toronto, ON M5G 2C1, Canada
  • James Lind Centro de Investigación del Cáncer
    Temuco, Araucania 4780000, Chile
  • Clinical Research Chile SpA
    Valdivia, Los Ríos Region 5090000, Chile
  • Centro de Estudios Clínicos SAGA
    Santiago, Chile
  • Clinica Alemana de Santiago
    Santiago, Chile
  • Clínica Santa María
    Santiago, Chile
  • Fundación Arturo López Pérez
    Santiago, Chile
  • Hospital Clinico Universidad de Chile
    Santiago, Chile
  • Aalborg University Hospital
    Aalborg, 9000, Denmark
  • Sjællands Universitetshospital
    Næstved, 4700, Denmark
  • Sønderborg Sygehus
    Sønderborg, 6400, Denmark
  • Vejle Hospital
    Vejle, 7100, Denmark
  • Hopital Jean Minjoz
    Besançon, 25030, France
  • AssAP-HP - Hopital Ambroise-Pare
    Boulogne-Billancourt, 92100, France
  • Hopital Morvan CHU de Brest
    Brest, 29200, France
  • Centre François Baclesse
    Caen, 14000, France
  • CHU de Caen - Hopital Cote de Nacre
    Caen, 14033, France
  • Centre Hospitalier Intercommunal de Creteil (CHIC)
    Créteil, 94000, France
  • Centre Hospitalier Universitaire CHU De Limoges
    Limoges, 87000, France
  • CHU de Nantes
    Nantes, Cedex 01 44093, France
  • Bichat-Claude Bernard Hospital
    Paris, 75018, France
  • CHU Reims - Hpital Maison Blanche
    Reims, 51092, France
  • Hopital Civil / Nouvel Hopital Civil
    Strasbourg, 67091, France
  • Hospital Foch
    Suresnes, 92150, France
  • Gustave Roussy
    Villejuif, 94805, France
  • High Technology Hospital Medcenter
    Batumi, 6000, Georgia
  • Todua Clinic
    Tbilisi, 112, Georgia
  • New Hospitals
    Tbilisi, 114, Georgia
  • Institute Of Clinical Oncology
    Tbilisi, 156, Georgia
  • JSC Evex Hospitals "Caraps Medline"
    Tbilisi, 179, Georgia
  • LTD Cancer Research Centre
    Tbilisi, 186, Georgia
  • LungenClinic Grosshansdorf
    Großhansdorf, Schleswig-Holstein 22927, Germany
  • Zentralklinik Bad Berka GmbH
    Bad Berka, 99437, Germany
  • Evangelische Lungenklinik Berlin
    Berlin, 13125, Germany
  • Klinikum Bremen Ost
    Bremen, 28325, Germany
  • Helios St. Johannes Klinikum
    Duisburg, 74166, Germany
  • Klinikum Esslingen GmbH
    Esslingen am Neckar, 73730, Germany
  • Universittsklinikum Freiburg
    Freiburg im Breisgau, 79106, Germany
  • Asklepios Fachklinik München-Gauting
    Gauting, 82131, Germany
  • Krankenhaus Martha-Maria Halle gGmbH
    Halle, 06120, Germany
  • Universitaetsklinikum Halle Saale
    Halle, 06120, Germany
  • Thoraxclinic Heidelberg GmbH
    Heidelberg, 69126, Germany
  • Vincentius-Diakonissen-Kliniken gAG Karlsruhe
    Karlsruhe, 76137, Germany
  • Klinikum Kassel - Medizinische Klinik IV
    Kassel, 34125, Germany
  • Klinik Loewenstein gGmbH
    Löwenstein, 74245, Germany
  • Universitaetsmedizin Mannheim
    Mannheim, 68167, Germany
  • Staedtisches Klinikum München - Bogenhausen
    München, 81925, Germany
  • Sana Klinikum Offenbach
    Offenbach, 63069, Germany
  • Debreceni Egyetem - Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Veszprem Megyei Tudogyogyintezet Farkasgyepu
    Farkasgyepű, 8582, Hungary

Showing the first 100 of 210 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Falcon A, Ponce S, Cote GM, Gil A, Lin JJ, Bockorny B, Martinez J, Kahatt C, Martinez S, Zubiaur P, Siguero M, Cullell-Young M, Jimenez J, Zugazagoitia J, Paz-Ares L. Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors. Invest New Drugs. 2025 Aug;43(4):955-967. doi: 10.1007/s10637-025-01583-y. Epub 2025 Sep 18. PubMed 40963055 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2026, 44 months.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 10, 2021
StartActual
Jul 22, 2022
Primary completionActual
Apr 10, 2026
CompletionActual
Apr 10, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05153239
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Dec 10, 2021
Start date
Jul 22, 2022
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · PM 01183

Start the discussion